CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
双特异性抗体治疗乳腺癌
英文原题：Bispecific antibodies for the treatment of breast cancer.
查看英文原题
Bispecific antibodies for the treatment of breast cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
短期内预计不会有 BsAb 获批用于乳腺癌，但后期试验正在进行中。鉴于雌激素受体+疾病、残留病灶和化疗降阶梯使用方面存在未满足需求，BsAb 未来在乳腺癌中可能发挥作用。HER2+领域显示出 BsAb 成功的迹象，但已经十分拥挤。未满足需求的领域仍然存在。
研究思路结论见上方概要
目前有超过二十多种双特异性抗体（BsAbs）正在开发中，其设计多种多样，与乳腺癌相关。乳腺癌BsAbs领域包括共导向免疫识别癌细胞、靶向独特癌症抗原以及靶向微环境的药物。BsAbs正被开发用作抗体-药物偶联物以及工程化T细胞的归巢信号。涵盖领域：本综述涵盖双特异性抗体的潜在靶点、临床前开发中的药物、临床试验中的药物、联合疗法以及未来方向。
展开英文摘要原文
INTRODUCTION: There are more than two dozen bispecific antibodies (BsAbs) in development with a variety of designs which are relevant to breast cancer. The field of BsAbs for breast cancer includes agents that co-direct immune recognition of the cancer cell, target unique cancer antigens, and target the microenvironment. BsAbs are being developed for use as antibody-drug conjugates and as homing signals for engineered T-cells.
AREAS COVERED: This review covers potential targets for bispecific antibodies, agents in pre-clinical development, agents in clinical trials, combinatorial therapies, and future directions. EXPERT OPINION: There is no BsAb approval expected for breast cancer in the near term, but late-stage trials are underway.
Future BsAb roles in breast cancer are possible given unmet needs in estrogen receptor+ disease, residual disease, and de-escalating chemotherapy use. The HER2+ space shows hints of success for BsAbs, but is already crowded. Areas of unmet need still exist.
论文信息
- 作者
- Dillon PM、Tushir-Singh J、Lum LG
- 单位
- Division of Hematology/Oncology, University of Virginia Charlottesville, VA, USA.United States
- 文献类型
- 综述 · 美国 NIH 资助研究
- 期刊
- Expert opinion on biological therapy2022 Aug
- 原文标识
- PubMed 33896311 · DOI 10.1080/14712598.2021.1922665
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →